TheraBiogen, Inc. Announces Agreement to Initiate Coverage by New To The Street

NEW YORK, NY--(Marketwire - June 30, 2011) - TheraBiogen, Inc. (OTCBB: TRAB) today announced an agreement for coverage by New To The Street including broadcasting nationally to 95 million homes.

TheraBiogen has just completed a TV profile interview with New To The Street that is being edited for broadcast later in the summer. In addition the video will be featured on NewToTheStreet.com and New to The Street Facebook and YouTube channel platforms. Additionally, FMW Media Works Corp., the parent company of New To The Street T.V., is creating 30 and 60 second commercials for Thera Max™ Cold and Flu Relief and Thera Max™ Allergy Relief. The broadcast could be seen repeatedly in an estimated 95 million homes.

Thera Max™ is available for purchase in thousands of locations from Rite-Aid, Walgreens Miami South District, Hannaford Supermarkets, Discount Drug Marts and Big Y Supermarkets. For more information on Thera Max™ visit our website www.theramaxrelief.com or our Facebook page at facebook.com/theramaxnasalspray.

About TheraBiogen, Inc.
TheraBiogen, Inc. is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com.

About FMW Media Works Corp.
FMW Media Works Corp. produces New To The Street, a television show that paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis and public company profiles. For more information visit NewToTheStreet.com and follow on twitter.com/newtothestreet.

Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.